BioSpace News Archive

Savings of up to 80 percent off Walgreens cash retail prices now available to members, as program expands to welcome those with Medicare and Medicaid coverage

Results supported recent U.S. FDA expedited approval of Jelmyto™ as the first non-surgical treatment for patients with this difficult-to-treat cancer

The Global Genes Continuity of Care RARE Patient Impact Grant Program Helps Rare Disease Members Obtain Life-Sustaining Services Disrupted by the COVID-19 Pandemic

Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) (“Cryoport” or the “Company”), a global leader in life sciences solutions, today announced that the Company will report financial results for the first quarter ended March 31, 2020 on Thursday, May 7, 2020 after U.S. markets close.

PDL BioPharma, Inc. (“PDL” or “the Company”) (Nasdaq: PDLI) announces that it will release its first quarter 2020 financial results for the period ended March 31, 2020 , on Thursday, May 7, 2020 , after market close. PDL’s management will host a conference call and webcast that day at 4:30 p.m. Eastern time to discu

CrO Biosciences, Inc., a privately held Life Sciences submissions management and inspection readiness consulting firm, announced Laura A. Jones as President.

Alveo Technologies , a leader in developing novel technologies that enable real-time, low-cost, at-home molecular detection of infectious disease, announced today that it has entered into a research collaboration with Janssen Pharmaceuticals, Inc., (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to advance Alveo’s be.well™ platform of analyzers, nasal swabs and cartridges for the dete

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Thursday, May 14, 2020 at 5:00 p.m. ET to report first quarter 2020 financial results and discuss recent business highlights. To access the live conference call, please dial 1-866-930-5579 (domestic)

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will release its first quarter 2020 financial results after the market closes on Thursday, May 14, 2020. Management will host a conference call with a slide presentation at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on th

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that it has submitted to the U.S. Food and Drug Administration (FDA) its protocol for a seamless adaptively-designed Phase 2b/3 clinical study, the NASH-RX trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin (GR-MD-02), for the prevention of esophageal varices in patients with non-alcohol